

02/13/03

1624

#9

Our Case: 446.018

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: : M. Berch
A. PEYMAN et al :
Serial No.: 10/030,290 : Group: 1624
Filed: December 31, 2001 :
For: SUBSTITUTED...CELL ADHESION :

600 Third Avenue
New York, N.Y. 10016
February 12, 2003

RESPONSE

Hon. Commissioner for Patents
Washington, D.C. 20231

Sir:

Responsive to the office action of January 13, 2003, Applicants request
reconsideration of the application in view of the remarks presented herein.

The Examiner has required a four-way restriction requirement between the claims
drawn to purines group I, imidazopyridines group II, pyrrolopyridines group III and
pyrazolopyrimidines, group IV. The Examiner was of the opinion that the groups were
patentably distinct since they had a distinct heterocyclic structure.

Applicants elect group I, namely those claims drawn to the purines, and reserve
the right to file divisional applications directed to the non-elected subject matter.

RECEIVED

FEB 19 2003


TECH CENTER 1600/2900

Express Mail[®] morning mail
Envelope - EV 243504010 US
Date of Deposit FEB 12 2003
I hereby certify that this paper or any its
pages are deposited with the United States Patent
and Trademark Office for the purpose of securing a
right of priority under 35 U.S.C. 119 on the date indicated
thereon and is addressed to the Commissioner
of Patents and Trademarks, Washington, D.C.

FEB. 12, 2003
S. Holmcey

Since the first office action was merely a restriction requirement, it is requested that a prompt examination on the merits be given.

Respectfully submitted,
Muserlian, Lucas and Mercanti



Charles A. Muserlian, 19,683
Attorney for Applicants
Tel. # (212) 661-8000

CAM:ds
Enclosures